The Wall Street Journal
12/31/2015
Express Scripts Turns to a Compounder to Avoid a Turing Drug
Express Scripts is arranging for patients to receive a lower-priced alternative to Daraprim.
Turing Pharmaceuticals AG raised the price of Daraprim after buying the U.S. rights from $13.50 to $750 a pill.
Drug-benefit manager Express Scripts Holding Co. said it is making arrangements with a drug compounder for patients to receive a lower-priced alternative to the expensive anti-parasitic pill Daraprim, whose price jumped more than 50-fold earlier this year. San Diego-based drug compounder Imprimis Pharmaceuticals Inc. makes customized medicines by mixing drug ingredients, and through their services patients under Express Scripts would be able to get the drug for $1 a capsule. The move could save millions of dollars a year in spending on Daraprim.
Read the full article here.
Share